- Home
- LCTX vs LNKB Comparison
LCTX vs LNKB Comparison
Compare LCTX & LNKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- LNKB
- Stock Information
- Founded
- LCTX 1990
- LNKB 2018
- Country
- LCTX United States
- LNKB United States
- Employees
- LCTX N/A
- LNKB N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- LNKB
- Sector
- LCTX Health Care
- LNKB
- Exchange
- LCTX Nasdaq
- LNKB Nasdaq
- Market Cap
- LCTX 274.0M
- LNKB 270.4M
- IPO Year
- LCTX N/A
- LNKB N/A
- Fundamental
- Price
- LCTX $1.44
- LNKB $7.40
- Analyst Decision
- LCTX Strong Buy
- LNKB Strong Buy
- Analyst Count
- LCTX 4
- LNKB 1
- Target Price
- LCTX $4.25
- LNKB $9.00
- AVG Volume (30 Days)
- LCTX 1.2M
- LNKB 34.1K
- Earning Date
- LCTX 11-13-2025
- LNKB 10-27-2025
- Dividend Yield
- LCTX N/A
- LNKB 4.12%
- EPS Growth
- LCTX N/A
- LNKB N/A
- EPS
- LCTX N/A
- LNKB 1.01
- Revenue
- LCTX $10,914,000.00
- LNKB $121,982,000.00
- Revenue This Year
- LCTX N/A
- LNKB $18.26
- Revenue Next Year
- LCTX $176.00
- LNKB N/A
- P/E Ratio
- LCTX N/A
- LNKB $7.22
- Revenue Growth
- LCTX 76.43
- LNKB 79.01
- 52 Week Low
- LCTX $0.37
- LNKB $6.09
- 52 Week High
- LCTX $1.42
- LNKB $7.98
- Technical
- Relative Strength Index (RSI)
- LCTX 69.73
- LNKB 52.53
- Support Level
- LCTX $1.20
- LNKB $7.03
- Resistance Level
- LCTX $1.42
- LNKB $7.53
- Average True Range (ATR)
- LCTX 0.07
- LNKB 0.19
- MACD
- LCTX 0.01
- LNKB -0.00
- Stochastic Oscillator
- LCTX 91.67
- LNKB 47.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.